Basilea Pharmaceutica AG (OTCMKTS:BPMUF – Get Free Report) shares reached a new 52-week high during mid-day trading on Tuesday . The company traded as high as $52.83 and last traded at $52.83, with a volume of 0 shares traded. The stock had previously closed at $52.83.
Wall Street Analyst Weigh In
Separately, HC Wainwright raised Basilea Pharmaceutica to a “strong-buy” rating in a research report on Monday, September 23rd.
Check Out Our Latest Report on BPMUF
Basilea Pharmaceutica Price Performance
Basilea Pharmaceutica Company Profile
Basilea Pharmaceutica AG, a commercial-stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. The company offers Cresemba, an intravenous and antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union.
Featured Articles
- Five stocks we like better than Basilea Pharmaceutica
- What Are the U.K. Market Holidays? How to Invest and Trade
- Home Depot Stock: Targeting 12% in 2024 and 25% More in 2025
- Are Penny Stocks a Good Fit for Your Portfolio?
- Is Tesla’s Valuation a Bubble or Backed by Real Growth?
- How the NYSE and NASDAQ are Different, Why That Matters to Investors
- Trucking Stocks Led the Pack Last Week: Can They Keep Rolling?
Receive News & Ratings for Basilea Pharmaceutica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Basilea Pharmaceutica and related companies with MarketBeat.com's FREE daily email newsletter.
